Tingting Xu

Mar 26, 2024 | mdpi.com | Xing LI |Tingting Xu |Ying Guo

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Jan 3, 2024 | onlinelibrary.wiley.com | Jingrui Hou |Tingting Xu |Bingyan Wang |Haoyuan Yang

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description adfm202312750-sup-0001-SuppMat.pdf3.1 MB Supporting Information adfm202312750-sup-0002-MovieS1.mp41.5 MB Supplemental Movie 1 adfm202312750-sup-0003-MovieS2.mp4372.9 KB Supplemental Movie 2 adfm202312750-sup-0004-MovieS3.mp41.2 MB Supplemental Movie 3 adfm202312750-sup-0005-MovieS4.mp46.1 MB Supplemental Movie 4 References 1a) , , , , , , , Adv. Funct.

Dec 6, 2023 | dx.doi.org | Tingting Xu |Yue Zhao

Inflammatory bowel disease (IBD) is a multifactorial chronic inflammation of the intestine and has become a global public health concern. A farnesoid X receptor (FXR) was recently reported to play a key role in hepatic-intestinal circulation, intestinal metabolism, immunity, and microbial regulation, and thus, it becomes a promising therapeutic target for IBD.

Jun 17, 2023 | mdpi.com | Tingting Xu |Yong Guo |Yuanyuan Zhang |Kai Cao

AltmetricshareShareannouncementHelpformat_quoteCitethumb_up... Endorsetextsms... CommentNeed Help? SupportFind support for a specific problem in the support section of our website. Get SupportFeedbackPlease let us know what you think of our products and services. Give FeedbackInformationVisit our dedicated information section to learn more about MDPI.